StreetInsider.com News Articles

Galderma Receives European Union Approval for Restylane® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping

Tue, 11 Aug 2026 01:00:00 -0400

Galderma has introduced the first-and-only shaper to the hyaluronic acid (HA) market with Restylane Shaype, now approved in the European Union (EU) for chin augmentation1
Restylane Shaype is the firmest HA gel available, powered by new NASHA HD™ technology, engineered to build and shape on bone for instant, natural-looking lower-face shaping from any angle1-3
It is the latest addition to the innovative Restylane portfolio – the world’s most diverse range of hyaluronic acid injectables designed to meet evolving aesthetic needs, backed by three decades of science4

ZUG, Switzerland--(BUSINESS WIRE)-- Galderma (SIX: GALD) today announced that Restylane Shaype has been

Galderma Receives European Union Approval for Restylane® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping

Tue, 11 Aug 2026 01:00:00 -0400

Galderma has introduced the first-and-only shaper to the hyaluronic acid (HA) market with Restylane Shaype, now approved in the European Union (EU) for chin augmentation1
Restylane Shaype is the firmest HA gel available, powered by new NASHA HD™ technology, engineered to build and shape on bone for instant, natural-looking lower-face shaping from any angle1-3
It is the latest addition to the innovative Restylane portfolio – the world’s most diverse range of hyaluronic acid injectables designed to meet evolving aesthetic needs, backed by three decades of science4

ZUG, Switzerland--(BUSINESS WIRE)-- Galderma (SIX: GALD) today announced that Restylane Shaype has been

Galderma Receives European Union Approval for Restylane® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping

Tue, 11 Aug 2026 01:00:00 -0400

Galderma has introduced the first-and-only shaper to the hyaluronic acid (HA) market with Restylane Shaype, now approved in the European Union (EU) for chin augmentation1
Restylane Shaype is the firmest HA gel available, powered by new NASHA HD™ technology, engineered to build and shape on bone for instant, natural-looking lower-face shaping from any angle1-3
It is the latest addition to the innovative Restylane portfolio – the world’s most diverse range of hyaluronic acid injectables designed to meet evolving aesthetic needs, backed by three decades of science4

ZUG, Switzerland--(BUSINESS WIRE)-- Galderma (SIX: GALD) today announced that Restylane Shaype has been

Galderma Receives European Union Approval for Restylane® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping

Tue, 11 Aug 2026 01:00:00 -0400

Galderma has introduced the first-and-only shaper to the hyaluronic acid (HA) market with Restylane Shaype, now approved in the European Union (EU) for chin augmentation1
Restylane Shaype is the firmest HA gel available, powered by new NASHA HD™ technology, engineered to build and shape on bone for instant, natural-looking lower-face shaping from any angle1-3
It is the latest addition to the innovative Restylane portfolio – the world’s most diverse range of hyaluronic acid injectables designed to meet evolving aesthetic needs, backed by three decades of science4

ZUG, Switzerland--(BUSINESS WIRE)-- Galderma (SIX: GALD) today announced that Restylane Shaype has been

Galderma Receives European Union Approval for Restylane® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping

Tue, 11 Aug 2026 01:00:00 -0400

Galderma has introduced the first-and-only shaper to the hyaluronic acid (HA) market with Restylane Shaype, now approved in the European Union (EU) for chin augmentation1
Restylane Shaype is the firmest HA gel available, powered by new NASHA HD™ technology, engineered to build and shape on bone for instant, natural-looking lower-face shaping from any angle1-3
It is the latest addition to the innovative Restylane portfolio – the world’s most diverse range of hyaluronic acid injectables designed to meet evolving aesthetic needs, backed by three decades of science4

ZUG, Switzerland--(BUSINESS WIRE)-- Galderma (SIX: GALD) today announced that Restylane Shaype has been

Galderma Receives European Union Approval for Restylane® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping

Tue, 11 Aug 2026 01:00:00 -0400

Galderma has introduced the first-and-only shaper to the hyaluronic acid (HA) market with Restylane Shaype, now approved in the European Union (EU) for chin augmentation1
Restylane Shaype is the firmest HA gel available, powered by new NASHA HD™ technology, engineered to build and shape on bone for instant, natural-looking lower-face shaping from any angle1-3
It is the latest addition to the innovative Restylane portfolio – the world’s most diverse range of hyaluronic acid injectables designed to meet evolving aesthetic needs, backed by three decades of science4

ZUG, Switzerland--(BUSINESS WIRE)-- Galderma (SIX: GALD) today announced that Restylane Shaype has been

Galderma Receives European Union Approval for Restylane® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping

Tue, 11 Aug 2026 01:00:00 -0400

Galderma has introduced the first-and-only shaper to the hyaluronic acid (HA) market with Restylane Shaype, now approved in the European Union (EU) for chin augmentation1
Restylane Shaype is the firmest HA gel available, powered by new NASHA HD™ technology, engineered to build and shape on bone for instant, natural-looking lower-face shaping from any angle1-3
It is the latest addition to the innovative Restylane portfolio – the world’s most diverse range of hyaluronic acid injectables designed to meet evolving aesthetic needs, backed by three decades of science4

ZUG, Switzerland--(BUSINESS WIRE)-- Galderma (SIX: GALD) today announced that Restylane Shaype has been

Galderma Receives European Union Approval for Restylane® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping

Tue, 11 Aug 2026 01:00:00 -0400

Galderma has introduced the first-and-only shaper to the hyaluronic acid (HA) market with Restylane Shaype, now approved in the European Union (EU) for chin augmentation1
Restylane Shaype is the firmest HA gel available, powered by new NASHA HD™ technology, engineered to build and shape on bone for instant, natural-looking lower-face shaping from any angle1-3
It is the latest addition to the innovative Restylane portfolio – the world’s most diverse range of hyaluronic acid injectables designed to meet evolving aesthetic needs, backed by three decades of science4

ZUG, Switzerland--(BUSINESS WIRE)-- Galderma (SIX: GALD) today announced that Restylane Shaype has been

Galderma expands Cetaphil's Nourishing Line with new body care innovations, delivering clinically proven glow through advanced barrier science

Wed, 05 Aug 2026 08:13:00 -0400

Developed specifically for sensitive skin, the Nourishing & Hydrating Lotion and Cream combine hyaluronic acid and skin-essential lipids to strengthen the skin barrier while delivering clinically proven glow.
Builds on the successful launch of the Cetaphil Nourishing Oil-to-Foam facial Cleanser, extending the Nourishing Line to body care.
Supported by clinical and consumer testing of the Nourishing & Hydrating Lotion, 92% of users reported their skin felt softer, smoother, and more radiant after just one use.

MIAMI, Aug. 5, 2026 /PRNewswire/ -- Galderma today announced that Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is

Galderma expands Cetaphil's Nourishing Line with new body care innovations, delivering clinically proven glow through advanced barrier science

Wed, 05 Aug 2026 08:13:00 -0400

Developed specifically for sensitive skin, the Nourishing & Hydrating Lotion and Cream combine hyaluronic acid and skin-essential lipids to strengthen the skin barrier while delivering clinically proven glow.
Builds on the successful launch of the Cetaphil Nourishing Oil-to-Foam facial Cleanser, extending the Nourishing Line to body care.
Supported by clinical and consumer testing of the Nourishing & Hydrating Lotion, 92% of users reported their skin felt softer, smoother, and more radiant after just one use.

MIAMI, Aug. 5, 2026 /PRNewswire/ -- Galderma today announced that Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is

Galderma expands Cetaphil's Nourishing Line with new body care innovations, delivering clinically proven glow through advanced barrier science

Wed, 05 Aug 2026 08:13:00 -0400

Developed specifically for sensitive skin, the Nourishing & Hydrating Lotion and Cream combine hyaluronic acid and skin-essential lipids to strengthen the skin barrier while delivering clinically proven glow.
Builds on the successful launch of the Cetaphil Nourishing Oil-to-Foam facial Cleanser, extending the Nourishing Line to body care.
Supported by clinical and consumer testing of the Nourishing & Hydrating Lotion, 92% of users reported their skin felt softer, smoother, and more radiant after just one use.

MIAMI, Aug. 5, 2026 /PRNewswire/ -- Galderma today announced that Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is

Galderma expands Cetaphil's Nourishing Line with new body care innovations, delivering clinically proven glow through advanced barrier science

Wed, 05 Aug 2026 08:13:00 -0400

Developed specifically for sensitive skin, the Nourishing & Hydrating Lotion and Cream combine hyaluronic acid and skin-essential lipids to strengthen the skin barrier while delivering clinically proven glow.
Builds on the successful launch of the Cetaphil Nourishing Oil-to-Foam facial Cleanser, extending the Nourishing Line to body care.
Supported by clinical and consumer testing of the Nourishing & Hydrating Lotion, 92% of users reported their skin felt softer, smoother, and more radiant after just one use.

MIAMI, Aug. 5, 2026 /PRNewswire/ -- Galderma today announced that Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is

Galderma expands Cetaphil's Nourishing Line with new body care innovations, delivering clinically proven glow through advanced barrier science

Wed, 05 Aug 2026 08:13:00 -0400

Developed specifically for sensitive skin, the Nourishing & Hydrating Lotion and Cream combine hyaluronic acid and skin-essential lipids to strengthen the skin barrier while delivering clinically proven glow.
Builds on the successful launch of the Cetaphil Nourishing Oil-to-Foam facial Cleanser, extending the Nourishing Line to body care.
Supported by clinical and consumer testing of the Nourishing & Hydrating Lotion, 92% of users reported their skin felt softer, smoother, and more radiant after just one use.

MIAMI, Aug. 5, 2026 /PRNewswire/ -- Galderma today announced that Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is

Galderma expands Cetaphil's Nourishing Line with new body care innovations, delivering clinically proven glow through advanced barrier science

Wed, 05 Aug 2026 08:13:00 -0400

Developed specifically for sensitive skin, the Nourishing & Hydrating Lotion and Cream combine hyaluronic acid and skin-essential lipids to strengthen the skin barrier while delivering clinically proven glow.
Builds on the successful launch of the Cetaphil Nourishing Oil-to-Foam facial Cleanser, extending the Nourishing Line to body care.
Supported by clinical and consumer testing of the Nourishing & Hydrating Lotion, 92% of users reported their skin felt softer, smoother, and more radiant after just one use.

MIAMI, Aug. 5, 2026 /PRNewswire/ -- Galderma today announced that Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is

Morgan Stanley bullish on Galderma on stronger Nemluvio growth outlook

Thu, 30 Jul 2026 09:13:22 -0400

Investing.com -- Morgan Stanley on Thursday upgraded Galderma Group AG to “overweight” from “equal-weight” and raised its price target to 210 Swiss francs from 160 Swiss francs, citing higher growth forecasts for the company’s Nemluvio drug and injectable aesthetics business after the Swiss dermatology company posted strong first-half 2026 results.

The new price target implies 19% upside from Galderma’s July 29 closing price of 177.10 Swiss francs.

Morgan Stanley said it raised its 2027-2030 forecasts by 5-6% on revenue, 2-5% on EBITDA and 9-11% on earnings per share, reflecting higher estimates for Nemluvio, a biologic drug for serious dermatology conditions,

Morgan Stanley bullish on Galderma on stronger Nemluvio growth outlook

Thu, 30 Jul 2026 09:13:22 -0400

The new price target implies 19% upside from Galderma’s July 29 closing price of 177.10 Swiss francs.

Galderma Reports Record First Half 2026 Net Sales of 3.134 Billion USD and 24.6% Year-on-Year Growth at Constant Currency, Raises Net Sales Guidance for the Full Year

Thu, 23 Jul 2026 01:00:00 -0400

Ad hoc announcement pursuant to Art. 53 LR